MindBio Therapeutics (XCNQ:MBIO) Change In Receivables : C$0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Change In Receivables?

MindBio Therapeutics's change in receivables for the quarter that ended in Mar. 2024 was C$-0.02 Mil. It means MindBio Therapeutics's Accounts Receivable increased by C$0.02 Mil from Dec. 2023 to Mar. 2024 .

MindBio Therapeutics's change in receivables for the fiscal year that ended in Jun. 2023 was C$0.00 Mil. It means MindBio Therapeutics's Accounts Receivable stayed the same from Jun. 2022 to Jun. 2023 .

MindBio Therapeutics's Accounts Receivable for the quarter that ended in Mar. 2024 was C$0.05 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. MindBio Therapeutics's Days Sales Outstanding for the three months ended in Mar. 2024 was 10.93.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. MindBio Therapeutics's liquidation value for the three months ended in Mar. 2024 was C$-5.01 Mil.

MindBio Therapeutics Change In Receivables Historical Data

The historical data trend for MindBio Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Change In Receivables Chart

MindBio Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Change In Receivables

-0.04

MindBio Therapeutics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial					-	-	0.02	-	-0.02

MindBio Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

MindBio Therapeutics (XCNQ:MBIO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

MindBio Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.046	/	0.384	*	91
=	10.93

2. In Ben Graham's calculation of liquidation value, MindBio Therapeutics's accounts receivable are only considered to be worth 75% of book value:

MindBio Therapeutics's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.231	-	5.272	+	0.75 * 0.046	+	0.5 * 0
=	-5.01

MindBio Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

WF6:Germany

Address

91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000

Website

https://www.mindbiotherapeutics.com

MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.